Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997636 | 0.86 | LOX (0.47) | MTNR1AMTNR1BLOXLOXL2 | |
| SCHEMBL19049394 | 0.86 | LOX (0.51) | MTNR1AMTNR1BLOXLOXL2 | |
| SCHEMBL6951705 | 0.86 | LOX (0.51) | MTNR1AMTNR1BLOXLOXL2 | |
| SCHEMBL19049441 | 0.86 | MTNR1A (0.61) | MTNR1AMTNR1BLOXLOXL2ACACB | |
| SCHEMBL24827539 | 0.85 | ALDH1A1 (0.47) | MTNR1AMTNR1BLOXLOXL2 | |
| SCHEMBL21740829 | 0.83 | KMT2A (0.45) | MTNR1AMTNR1BLOXLOXL2 | |
| SCHEMBL18997700 | 0.82 | LOX (0.48) | MTNR1AMTNR1BLOXLOXL2 | |
| SCHEMBL24827596 | 0.82 | LOX (0.48) | MTNR1AMTNR1BLOXLOXL2ACACB | |
| SCHEMBL19001318 | 0.81 | MTNR1A (0.54) | MTNR1AMTNR1BACACB | |
| SCHEMBL19002285 | 0.79 | ACACB (0.51) | MTNR1AMTNR1BACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MTNR1A 1704/4885MTNR1B 1599/4885LOX 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.